Gyre Therapeutics, Inc.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2021 | — | $41.1M | $44.3M |
| FY2022 | — | $42.5M | $25.2M |
| FY2023 | — | $-15.8M | $33.5M |
| FY2024 | — | $63.3M | $11.8M |
| FY2025 | — | $106.0M | $37.1M |
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2021 | — | $41.1M | $44.3M |
| FY2022 | — | $42.5M | $25.2M |
| FY2023 | — | $-15.8M | $33.5M |
| FY2024 | — | $63.3M | $11.8M |
| FY2025 | — | $106.0M | $37.1M |